Isto Technologies is a technology company.
Isto Technologies has raised $9.0M across 1 funding round.
Isto Technologies has raised $9.0M in total across 1 funding round.
Isto Technologies has raised $9.0M in total across 1 funding round.
Isto Technologies's investors include Alafi Capital, Ascension Ventures.
ISTO Technologies is a regenerative medicine company focused on developing proprietary biologics products for spinal therapies, sports medicine, orthopedics, and cartilage/bone repair to improve patient quality of life.[1][2][5] It offers autologous therapies like the Magellan® Autologous Concentration System for Platelet Rich Plasma (PRP) and Concentrated Bone Marrow Aspirate, allografts under the Influx™ line (e.g., ProteiOS, Fibrant), and synthetics like InQu® biosynthetic bone graft, serving surgeons, physicians, hospitals, and distributors in orthobiologics.[2] Founded in 1997 and based in St. Louis, Missouri (with some operations noted in Hopkinton, MA), the company raised $38.56M before merging into Isto Biologics, expanding its portfolio with Advanced Biologics' products alongside Influx allografts as of October 2023.[1][3]
As a portfolio-style biotech firm now operating as a pureplay biologics company under Isto Biologics, it targets patient healing acceleration through customizable bone grafts and concentration systems, addressing challenges in spine, orthopedics, and sports medicine with a focus on innovation and clinical efficacy outperforming traditional iliac crest bone graft (ICBG).[2]
ISTO Technologies was founded in 1997 in St. Louis, Missouri, initially dedicated to regenerative medicine for spinal therapies and sports medicine applications, developing products for cartilage and bone repair.[1] Early efforts included cell-based therapies for degenerative disc disease and chondrocyte-based treatments for knee disorders and intervertebral disc degeneration, though several drug pipelines reached discontinued phases in clinical trials starting around 2012-2013.[4]
A pivotal moment came with its merger into TSCP's Isto Biologics in October 2023, integrating Advanced Biologics' proprietary products to broaden its orthobiologics portfolio, evolving from a standalone developer to a leader in autologous therapies and bone grafts.[1][2] This transition humanizes its story as a persistent innovator listening to surgeon needs amid biotech challenges.
ISTO Technologies rides the orthobiologics trend in regenerative medicine, capitalizing on rising demand for biologics in spine, orthopedics, and sports medicine amid aging populations and minimally invasive procedures.[1][2][5] Timing aligns with post-merger expansion in 2023, when autologous therapies and advanced grafts gained traction for faster healing over autografts, fueled by market forces like surgeon adoption of PRP/CBMA and synthetics reducing donor site morbidity.[2]
It influences the ecosystem by providing customizable tools that enhance surgical outcomes, supporting a shift toward biologics in orthopedic applications and enabling broader access via partners, while contributing to discontinued-but-insightful trials in disc regeneration.[1][4]
Isto Biologics, post-ISTO merger, is poised to deepen orthobiologics dominance with ongoing innovation in autologous and graft tech, potentially launching next-gen Precise™ variants or Influx expansions.[2] Trends like AI-optimized biologics personalization and global orthopedics growth (driven by sports injuries and spinal degeneration) will shape its path, amplifying influence through stronger surgeon networks and clinical data.
This positions it centrally in patient healing acceleration, evolving from spinal pioneer to comprehensive biologics leader.[1][2]
Isto Technologies has raised $9.0M across 1 funding round. Most recently, it raised $9.0M Series E in August 2007.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Aug 1, 2007 | $9.0M Series E | Alafi Capital, Ascension Ventures |